OTCMKTS:MEOBF Mesoblast - MEOBF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. $0.74 0.00 (0.00%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.74▼$0.7450-Day Range$0.57▼$0.7452-Week Range$0.44▼$0.86VolumeN/AAverage Volume1,400 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest About Mesoblast (OTCMKTS:MEOBF) StockMesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.Read More Receive MEOBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address MEOBF Stock News HeadlinesJanuary 11, 2023 | finance.yahoo.comMesoblast Limited (MEOBF) Stock Historical Prices & Data - Yahoo FinanceSeptember 29, 2022 | reuters.comMESO.O - Mesoblast limited (ADR) | Stock Price & Latest News | ReutersMarch 22, 2023 | Investing Daily (Ad)How This Trader Banked A 97% Win RateDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. September 29, 2022 | investing.comMesoblast Teva StartsSeptember 1, 2022 | seekingalpha.comMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptSeptember 1, 2022 | seekingalpha.comMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationMay 25, 2022 | markets.businessinsider.comMindMed Appoints Schond L. Greenway As CFOMay 25, 2022 | benzinga.comMesoblast (OTC:MEOBF), Short Interest ReportMarch 22, 2023 | Investing Daily (Ad)How This Trader Banked A 97% Win RateDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. May 25, 2022 | benzinga.comMesoblast (OTC:MEOBF), Earnings Estimates, EPS, and RevenueApril 29, 2022 | seekingalpha.comMesoblast reports FQ3 resultsMarch 28, 2022 | fool.comMesoblast Limited (MESO) Q1 2022 Earnings Call TranscriptAugust 31, 2021 | markets.businessinsider.comWhy Mesoblast Stock Is Plunging After Q4 Earnings Report?August 24, 2021 | finance.yahoo.comLoss-Making Mesoblast Limited (ASX:MSB) Expected To Breakeven In The Medium-TermJuly 19, 2021 | finance.yahoo.comMesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS TrialJuly 18, 2021 | benzinga.comNinety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung DiseasesJuly 15, 2021 | finance.yahoo.comMesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease ConferenceJuly 1, 2021 | finance.yahoo.comMesoblast Updates On Rexlemestrocel-L Program In Chronic Low Back PainJune 30, 2021 | finance.yahoo.comMesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc DiseaseJune 25, 2021 | finance.yahoo.comIs Mesoblast (ASX:MSB) Using Debt Sensibly?June 2, 2021 | finance.yahoo.comOperational Highlights and Financial Results for the Period Ended March 31, 2021June 2, 2021 | markets.businessinsider.com Mesoblast Corporate Update and Financial Results WebcastMay 25, 2021 | finance.yahoo.comImproved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research JournalMay 3, 2021 | finance.yahoo.comStrength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?March 30, 2021 | finance.yahoo.comMesoblast Operational Highlights and Upcoming MilestonesMarch 29, 2021 | finance.yahoo.comPhilip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast BoardFebruary 10, 2021 | finance.yahoo.comMesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc DiseaseSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MEOBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MEOBF CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesSilviu ItescuChief Executive Officer, MD & Executive DirectorDagmar Rosa-BjorkesonChief Operating OfficerAndrew ChaponnelChief Financial Officer & Head-FinanceEric A. RoseExecutive Director & Chief Medical OfficerMichael SchusterHead-Pharma PartneringKey Competitors3SBioOTCMKTS:TRSBFAbattis BioceuticalsOTCMKTS:ATTBFAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAinosNASDAQ:AIMDWView All Competitors MEOBF Stock - Frequently Asked Questions How have MEOBF shares performed in 2023? Mesoblast's stock was trading at $0.5749 at the beginning of the year. Since then, MEOBF stock has increased by 28.5% and is now trading at $0.7389. View the best growth stocks for 2023 here. Are investors shorting Mesoblast? Mesoblast saw a increase in short interest in February. As of February 15th, there was short interest totaling 2,481,700 shares, an increase of 591.7% from the January 31st total of 358,800 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days. View Mesoblast's Short Interest. What is Mesoblast's stock symbol? Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF." How do I buy shares of Mesoblast? Shares of MEOBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mesoblast's stock price today? One share of MEOBF stock can currently be purchased for approximately $0.74. How can I contact Mesoblast? Mesoblast's mailing address is 55 Collins Street, Melbourne, Victoria (VIC). The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036. This page (OTCMKTS:MEOBF) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.